Compare Biogen Inc (BIIB) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Coursera Inc — how do they compare? Biogen Inc trades at $206.92 (market cap $30.13B), while Coursera Inc trades at $5.53 (market cap $1.50B). The key difference: Biogen Inc is far larger — about 20.1× Coursera Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | COUR | |
|---|---|---|
Market Cap | $30.13B | $1.50B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $12.20 |
52-Week Low | $128.93 | $5.09 |
Enterprise Value | $37.20B | $759.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
COUR trades at $5.76, down 0.86% today, with a neutral technical signal. Revenue grew to $757.5M in 2025, but net income remains negative at -$51M. The company recently beat Q2 2026 EPS estimates at $0.17 versus $0.10 expected. Positive cash flow from operations of $108.7M in 2025 supports liquidity, while a $100M investment in LearnVector highlights strategic AI focus.
Outlook is mixed: analyst consensus is bullish with a $7.70 price target (34% upside), but persistent losses and competitive pressures pose risks. The stock offers growth potential if profitability improves, yet high SG&A costs and integration challenges from the Udemy acquisition require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
